[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352319-105":59,"doc-detail-352319-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","modelling-immune-dynamics-in-locally-advanced-msi-hdmmr-colorectal-cancer-with-neoadjuvant-pembrolizumab-treatment-from-differential-equations-to-an-agent-based-framework","Modelling Immune Dynamics in Locally Advanced MSI-H/dMMR Colorectal Cancer with Neoadjuvant Pembrolizumab Treatment: From Differential Equations to an Agent-Based Framework","","Colorectal cancer remains a major global malignancy, with MSI-H/dMMR tumours characterized by high mutational burden and neoantigen load that can still evade immune surveillance via PD-1/PD-L1 signalling. Neoadjuvant pembrolizumab for locally advanced MSI-H/dMMR CRC is investigated using a minimal ordinary-differential-equation model to capture key immune dynamics. The ODE model, calibrated to experimental data, is converted into an agent-based framework to retain dynamics while enabling stochastic, individual-level interactions and discrete events beyond ODE scope.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/modelling-immune-dynamics-in-locally-advanced-msi-hdmmr-colorectal-cancer-with-neoadjuvant-pembrolizumab-treatment-from-differential-equations-to-an-agent-based-framework/352319/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/modelling-immune-dynamics-in-locally-advanced-msi-hdmmr-colorectal-cancer-with-neoadjuvant-pembrolizumab-treatment-from-differential-equations-to-an-agent-based-framework/352319.png","ImageObject",300,407,{"name":92,"@type":93},"Ivy","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What biological challenges in MSI-H/dMMR colorectal cancer motivate using pembrolizumab in the locally advanced setting?","Question",{"text":112,"@type":113},"MSI-H/dMMR tumours are highly immunogenic but can evade immune surveillance through PD-1/PD-L1-mediated signalling. Pembrolizumab blocks PD-1, aiming to restore anti-tumour immune responses and improve outcomes in locally advanced disease.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the study’s minimal ODE model relate to immune dynamics under neoadjuvant pembrolizumab treatment?",{"text":117,"@type":113},"The work constructs a minimal model using ordinary differential equations to capture the main immune dynamics involved in neoadjuvant pembrolizumab therapy for locally advanced MSI-H/dMMR CRC.",{"name":119,"@type":110,"acceptedAnswer":120},"Why convert the ODE model into an agent-based model (ABM)?",{"text":121,"@type":113},"The ABM approach naturally supports stochasticity, individual-level interactions, and discrete events that differential-equation formulations do not cover. The conversion preserves the calibrated dynamics while providing a flexible platform for future mechanistic investigation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352319,1790468188,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":24,"preview_urls":146},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","Bulletin of Mathematical Biology (2026) 88:35  \n[https://doi.org/10.1007/s1](https://doi.org/10.1007/s1)1538-026-01594-7  \nORIGINAL ARTICLE  \nModelling Immune Dynamics in Locally Advanced  \nMSI-H/dMMR Colorectal Cancer with Neoadjuvant Pembrolizumab Treatment: From Differential Equations to an Agent-Based Framework  \nGeorgio Hawi1 · Peter S. Kim1 · Peter P. Lee2  \nReceived: 16 September 2025 / Accepted: 1 January 2026 / Published online: 2 February 2026 © The Author(s) 2026  \nAbstract  \nColorectal cancer (CRC) is the third most common malignancy worldwide, and accounts for approximately 10% of all cancers and an estimated 850,000 deaths annually. Within CRC, MSI-H/dMMR tumours are highly immunogenic due to their high mutational burden and neoantigen load, yet can evade immunosurveillance via PD- 1/PD-L1-mediated signalling. Pembrolizumab, an anti-PD-1 antibody approved for unresectable or metastatic MSI-H/dMMR CRC, is emerging as a promising neoadjuvant option in the locally advanced setting, inducing rapid, deep and durable immune responses. In this work, we construct a minimal model of neoadjuvantpembrolizumab therapyin locally advancedMSI-H/dMMR CRC(laMCRC)using ordinary differential equations (ODEs), providing a highly extensible model that captures the main immune dynamics involved. On the other hand, agent-based models (ABMs) naturally capture stochasticity, interactions at an individual level, and discrete events that lie beyond the scope of differential-equation formulations. As such, we also convert our ODE model, with parameters calibrated to experimental data, to an ABM, preserving its dynamics while providing a ﬂexible platform for future mechanistic investigation and modelling.  \nKeywords Locally advanced MSI-H/dMMR colorectal cancer · Pembrolizumab · ordinary differential equations · Agent-based modelling · Minimal model  \nP.S. Kim and P.P. Lee have contributed comparably to this work.  \nB Georgio Hawi [georgio.hawi@sydney.edu.au](georgio.hawi@sydney.edu.au)  \n1 School of Mathematics and Statistics, University of Sydney, Sydney, Australia  \n2 Department of Immuno-Oncology, Beckman Research Institute, City of Hope, Duarte, California, USA  \n1 Introduction  \nColorectal cancer(CRC)—the world’s third most common malignancy, accounting for approximately 10% of all cancers (Klimeck et al. 2023) and more than 1.85 million cases with850,000deaths annually(Billerand Schrag2021)—remains a majorburden, with the American Cancer Society projecting 154,270 new CRC diagnoses and 52,900 deaths in the United States due to CRC in 2025 (Siegel et al. 2025) . A key phenotype within CRC is that of microsatellite instability–high/mismatch repair–deﬁcient (MSIH/dMMR) disease, characterised by a highly immunogenic tumour microenvironment (TME) driven by markedly elevated somatic mutation rates, tumour mutational burden (TMB), and neoantigen load (Mulet-Margalef et al. 2023; Llosa et al. 2015 ; Giannakis et al. 2016) . Although approximately 20% of stage II and 12% of stage III CRC tumours are MSI-H/dMMR (Sinicrope et al. 2011; Fan et al. 2024), patients with this hypermutant phenotype respond poorly to conventional 5-ﬂuorouracil–based chemotherapy (Gu et al. 2019; Shulman et al. 2018) yet show striking responsiveness to immune checkpoint inhibitors (ICIs) (Ciardiello et al. 2019) .  \nImmune checkpoints, such as programmed cell death-1 (PD-1), a cell membrane receptor that is expressed on a variety of cell types, including activated T cells, activated NK cells and monocytes, normally downregulate immune responses after antigen activation (Topalian et al. 2012). PD-1 has been extensively studied in cancer, including MSI-H/dMMR CRC (Sarshekeh et al. 2018; Yaghoubi et al. 2019); engagement by its ligands PD-L1 and PD-L2 inhibits effector T-cell activity, suppresses pro-inﬂammatory cytokine secretion, and promotes expansion of regulatory T cells (Tregs) (Lin et al. 2024; Han et al. 2020) . Tumours further exploit this pathway by expressing P","cbCaihKdI8mdSEAJ","https://ap.wps.com/l/cbCaihKdI8mdSEAJ","pdf",5752866,44,"English","# Abstract\n# Introduction","[{\"question\":\"What biological challenges in MSI-H/dMMR colorectal cancer motivate using pembrolizumab in the locally advanced setting?\",\"answer\":\"MSI-H/dMMR tumours are highly immunogenic but can evade immune surveillance through PD-1/PD-L1-mediated signalling. Pembrolizumab blocks PD-1, aiming to restore anti-tumour immune responses and improve outcomes in locally advanced disease.\"},{\"question\":\"How does the study’s minimal ODE model relate to immune dynamics under neoadjuvant pembrolizumab treatment?\",\"answer\":\"The work constructs a minimal model using ordinary differential equations to capture the main immune dynamics involved in neoadjuvant pembrolizumab therapy for locally advanced MSI-H/dMMR CRC.\"},{\"question\":\"Why convert the ODE model into an agent-based model (ABM)?\",\"answer\":\"The ABM approach naturally supports stochasticity, individual-level interactions, and discrete events that differential-equation formulations do not cover. The conversion preserves the calibrated dynamics while providing a flexible platform for future mechanistic investigation.\"}]","Modelling Immune Dynamics in Locally Advanced MSI-H/dMMR Colorectal Cancer with Neoadjuvant Pembrolizumab Treatment: From Differential Equations to an Agent-Based Framework | PDF",1790098938,111,[147,151,155,159,163],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4dc5c7e0dbcf660a5c0cd14bc74b4cb2.webp",983,1415,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6e83b9951b3d2201af20b2867ef8b22a.webp",982,1414,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/11039684e75d57e5532622d166f838cd.webp",981,1412,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1a51e48defc2d1648517a0815e1a3d28.webp",980,1411,{"page_no":24,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/55a1b5e6816395864b85fc15d1d2752e.webp",979,1409]